COMPANY SUMMARY
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Financial Summary
| Share Statistics |
NEOG |
Industry Median |
Percentile (All Stocks) |
| Market Cap (Mil) |
$2,661.2 |
$404.5 |
59% |
|
| Shares Out (Mil) |
218.1 |
41.2 |
78% |
|
| Institutional Ownership |
99.6% |
83.3% |
91% |
|
| Float (Mil) |
217.3 |
35.5 |
75% |
|
| Beta |
1.79 |
0.85 |
88% |
|
| Avg Daily Volume (000s) |
2,699 |
259 |
86% |
|
Price Change (52-week) |
98.5% |
62.9% |
95% |
|
| Growth |
NEOG |
Industry Median |
Percentile (All Stocks) |
| Sales (5yr) |
13.2% |
11.8% |
69% |
|
| Net Income (5yr) |
(16.3%) |
(4.8%) |
24% |
|
| EPS (5yr) |
(15.7%) |
10.6% |
18 |
|
| Dividends (5yr) |
0.0% |
0.0% |
0% |
|
| Cash Flow (5yr) |
23.6% |
(15.6%) |
82% |
|
| Estimates |
Qtrly |
Current Fiscal Year |
Next Fiscal Year |
| # of Estimates |
3 |
3 |
2 |
| Current EPS |
$0.063 |
$0.333 |
$0.450 |
| Month Ago EPS |
$0.093 |
$0.310 |
$0.430 |
| # Rev Up |
0 |
1 |
1 |
| # Rev Down |
1 |
0 |
0 |
| Three Months Ago EPS |
$0.097 |
$0.300 |
$0.420 |
| Year/Year Chg |
(214.5%) |
(932.5%) |
(1,650%) |
| Financials |
NEOG |
Industry Median |
Percentile (All Stocks) |
| Sales (TTM) (Mil) |
$884 |
$155 |
49% |
|
| Net Income (TTM) (Mil) |
($56) |
($9) |
15% |
|
| EPS (TTM) |
($0.258) |
($0.400) |
32% |
|
| Operating Cash Flow (TTM) (Mil) |
$85 |
($2) |
51% |
|
| Net Cash Flow (TTM) (Mil) |
$33 |
$1 |
66% |
|
| Long-Term Debt (Q1) (Mil) |
$774 |
$28 |
63% |
|
| Enterprise Value (Q1) (Mil) |
$3,159 |
$437 |
56% |
|
| Valuation |
NEOG |
Industry Median |
Percentile (All Stocks) |
| P/B |
1.28 |
2.52 |
36% |
|
| P/E |
na |
26.8 |
na |
|
| Dividend Yield |
0.0% |
0.0% |
0% |
|
| PEG (5yr hist) |
na |
1.5 |
na |
|
| Ratios |
NEOG |
Industry Median |
Percentile (All Stocks) |
| Gross Margin |
47.4% |
59.0% |
59% |
|
| Net Margin |
(6.3%) |
(6.9%) |
24% |
|
| ROA |
(1.7%) |
(12.2%) |
35% |
|
| ROE |
(2.7%) |
(10.5%) |
33% |
|
| Liabilities to Assets |
36.8% |
47.2% |
28% |
|
| F-Score |
6 |
4 |
67% |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
NEOG meetings the criteria of 1 screen:
Stock Screen
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.